A panelist discusses how their institution implements robust safety protocols including distinct labeling, electronic health record alerts, and staff education to prevent dispensing errors when managing multiple biosimilars, while also conducting targeted educational outreach to address stakeholder concerns about interchangeability.

An expert discusses the management plan for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), highlighting approaches beyond pharmacotherapies.

An expert discusses the key side effects and contraindications associated with antifibrotic agents and how to monitor for and manage them.

An expert discusses treatments for narcolepsy, comparing options for managing excessive daytime sleepiness (EDS) and cataplexy, and examines the advantages, limitations, and clinical scenarios for medications targeting EDS versus compared with those for both EDS and cataplexy.

A panelist discusses how neurokinin-targeted therapies can be strategically combined with existing treatments to address multiple vasomotor symptoms (VMS) while highlighting their positive impact on patient quality of life, noting ongoing needs for long-term safety data and improved accessibility.

A panelist discusses how payer contract requirements and reimbursement policies significantly influence their institution’s biosimilar adoption strategy, requiring careful analysis of net cost benefits when weighing potential savings against the operational complexities of managing multiple products.

An expert discusses how nintedanib and pirfenidone differ in their mechanisms of action and efficacy in treating idiopathic pulmonary fibrosis (IPF).

An expert discusses the current understanding of corticosteroids in managing pulmonary fibrosis and how it has evolved in recent years, and identifies specific patient populations for whom steroids may remain a viable treatment option.

An expert discusses how key symptoms of narcolepsy, such as excessive daytime sleepiness and cataplexy, impact daily functioning and quality of life, along with the primary differences between type 1 and type 2 narcolepsy in terms of pathophysiology, clinical presentation, and diagnostic criteria.